AI is transforming software. But what happens when it starts transforming biology?
In this episode of Machine Dreams, we sit down with Maya Ashkenazi-Otmazin, founder and CEO of Maolac, to explore how AI is being used to understand and design full proteins, not just small molecules, but the building blocks of human biology itself.
From breast milk as nature’s survival blueprint to the challenges of limited biological training data, this conversation looks at what it really means to use machine learning in drug discovery. We unpack the promise, the risks, and the uncomfortable truth about how slowly biology has advanced compared to tech.
This isn’t hype about curing everything tomorrow. It’s a grounded conversation about where AI in therapeutics actually stands, and what it would take to responsibly move faster.
Full episode live at 7pm GMT+1. 6pm UK. 1pm EST.
